Dat

Mersana Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, November 6, 2019
Drugs, RTT, Dat, Dose, MG Cars, Medroxyprogesterone acetate, 7+3

In August 2019, Mersana announced that it had dosed the first patient in the expansion study on the 36 mg/m2 once-every-four-week dose regimen.

Key Points: 
  • In August 2019, Mersana announced that it had dosed the first patient in the expansion study on the 36 mg/m2 once-every-four-week dose regimen.
  • In August 2019, Mersana announced that the 36 mg/m2 once-every-four-week dosing cohort cleared safety review and the Company initiated a 43 mg/m2 once-every-four-week dose escalation cohort.
  • Collaboration revenue for the third quarter 2019 was approximately $0.8 million, compared to $2.2 million for the same period in 2018.
  • ET to report financial results for the third quarter of 2019 and provide certain business updates.

Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development

Retrieved on: 
Monday, October 28, 2019
Drugs, Analgesics, RTT, Chemical compounds, Hepatotoxins, Amines, Cyclohexanols, Tramadol, Dat, Paracetamol, 7+3, Nonsteroidal anti-inflammatory drug

NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, announced today that its Phase 1 data on intravenous (IV) tramadol has been published in the peer-reviewed journal Clinical Pharmacology in Drug Development.

Key Points: 
  • NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, announced today that its Phase 1 data on intravenous (IV) tramadol has been published in the peer-reviewed journal Clinical Pharmacology in Drug Development.
  • Based on the results of the study, Avenue chose the IV tramadol 50 mg dosing regimen for Phase 3 development.
  • The IV tramadol 50 mg dosing regimen was well tolerated, with adverse event profiles consistent with the known pharmacological effects of tramadol.
  • IV tramadol may fill a gap in the acute pain market between IV acetaminophen/NSAIDs and IV conventional narcotics.

Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

Retrieved on: 
Thursday, September 26, 2019
Medicine, Gastroenterology, Pediatric gastroenterology, Pediatrics, Dat, Health, Clinical medicine

These data were presented at the World Congress of Gastroenterology Meeting in Istanbul, Turkey.

Key Points: 
  • These data were presented at the World Congress of Gastroenterology Meeting in Istanbul, Turkey.
  • "In addition to previously reported dose-response data from OASIS, these new findings further strengthen the etrasimod 2 mg dosing regimen chosen for our Phase 3 ELEVATE UC program."
  • These data will be encored at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) 2019 Annual Meeting , and the American Association of Pharmaceutical Scientists (AAPS) 2019 PHARMSCI 360 Meeting .
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

SPIDA® Software Unveils SPIDAmin One Touch Make Ready Workflows and Enhanced Security Features

Retrieved on: 
Tuesday, March 26, 2019
Telecommunications, Articles, Business, Local government in the United States, One Touch Make Ready, Telecommunications equipment, Workflow, Dat

With this release, SPIDA introduces One Touch Make Ready (OTMR) workflows and enhanced security features, staying ahead of industry trends.

Key Points: 
  • With this release, SPIDA introduces One Touch Make Ready (OTMR) workflows and enhanced security features, staying ahead of industry trends.
  • SPIDAmin One Touch Make Ready workflows provide the necessary framework for successful implementation of the new guidelines.
  • In addition to introducing OTMR workflows, this release includes a robust set of enhanced security features, safeguarding client data.
  • "SPIDAmin's enhanced security and new One Touch Make Ready workflows are prime examples of our commitment to innovative software solutions aimed at helping organizations adapt and thrive in an ever-changing industry", said Trent Quatman, Product Lead at SPIDA Software.

Paxata Accelerates Enterprise Data Prep with New Intelligent Automation of Data Projects

Retrieved on: 
Monday, March 18, 2019
Technology, Data management, Internet, Networks, Software, Computing, Big data, Business, Digital technology, Analytics, DataOps, Performance management, Automation, Paxata, Workflow, Dat, Profiling

Paxata's new Intelligent Automation capability allows our business and data analysts to collaborate across multiple data prep projects and then automate them into a single flow with a simple click of a button, said Jim Tyo, Chief Data Officer, Nationwide Insurance.

Key Points: 
  • Paxata's new Intelligent Automation capability allows our business and data analysts to collaborate across multiple data prep projects and then automate them into a single flow with a simple click of a button, said Jim Tyo, Chief Data Officer, Nationwide Insurance.
  • With Paxata Spring 2019, organizations can now accelerate their data prep and DataOps journey in a single, integrated platform.
  • The new release empowers all contributors - such as data analysts, data engineers, and citizen data scientists - across various data initiatives by enabling crowdsourcing and collaboration of not only data profiling and data preparation tasks, but also cataloging, operationalizing and monitoring of workflows.
  • Building upon its previous intelligent capabilities across data ingestion, data profiling, and data preparation, Paxatas Intelligent Automation now offers built-in smart algorithms for operationalizing and automating workflows.

BSD Invests in Expanding Leadership Team as Company Growth Accelerates with the Launch of SpecLink Cloud

Retrieved on: 
Friday, July 27, 2018
Software engineering, University of California, Berkeley, Technology, Computer architecture, Berkeley Software Distribution, Specification, Dat

"The response to the launch of SpecLink Cloud at this year's Construction Specifications Canada and AIA conferences was overwhelming, and we're growing quickly to accommodate increased demand," said Chris Anderson, President, and CEO of BSD.

Key Points: 
  • "The response to the launch of SpecLink Cloud at this year's Construction Specifications Canada and AIA conferences was overwhelming, and we're growing quickly to accommodate increased demand," said Chris Anderson, President, and CEO of BSD.
  • "This expansion speaks to BSD's dedication to the success of architects, specifiers, owners and product manufacturers who use SpecLink."
  • Paul Worosz will lead the BPM team, Kristin Tiliakos the AEC team and Laura Dempsey the Owner team.
  • For more information on BSD, visit www.bsdspeclink.com
    To stay up-to-date on BSD news, visit our press release page .